STOCK TITAN

Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT) announced it will report financial results for Q1 2022 on May 10, 2022, after market close. Management will hold a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The company focuses on innovative eyecare solutions like the OMNI® Surgical System and TearCare® System, targeting prevalent eye diseases. Interested investors can access the call through their website or via dial-in options. These systems provide minimally invasive treatments for conditions like glaucoma and dry eye disease.

Positive
  • The company is preparing to report financial results, indicating transparency and engagement with investors.
  • Focus on innovative technologies like OMNI® and TearCare® that target significant health issues in eyecare, potentially driving future growth.
Negative
  • None.

MENLO PARK, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 844-287-7410 (U.S.) or 914-800-3942 (International) five to ten minutes prior to the start time, using the passcode: 5193467.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.

Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com


FAQ

When will Sight Sciences report financial results for Q1 2022?

Sight Sciences will report financial results for Q1 2022 on May 10, 2022.

What time is the conference call for Sight Sciences Q1 earnings?

The conference call for Sight Sciences' Q1 earnings is scheduled for 1:30 p.m. PT / 4:30 p.m. ET.

How can investors access the Sight Sciences conference call?

Investors can access the conference call through a live webcast on the Sight Sciences website or by dialing in at 844-287-7410 (U.S.) or 914-800-3942 (International) with the passcode: 5193467.

What are the main technologies developed by Sight Sciences?

Sight Sciences specializes in the OMNI® Surgical System for glaucoma treatment and TearCare® System for evaporative dry eye disease.

Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Stock Data

204.36M
40.24M
19.9%
51.1%
2.23%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MENLO PARK